GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)’s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch. Continue reading “GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis”

Investing In Marijuana: Cannabis Industry Raises Hit $1.8 Billion, Up 150% Year Over Year

Despite strong opposition from former White House Press Secretary Sean Spicer and Attorney General Jeff Sessions, and the overall limitations imposed by federal illegality in the U.S., 2017 is shaping up to be a great year for the North American cannabis in Continue reading “Investing In Marijuana: Cannabis Industry Raises Hit $1.8 Billion, Up 150% Year Over Year”

What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial Continue reading “What Zynerba’s Flop Means For CBD Therapies And GW Pharmaceuticals”

GW Pharma Takes A Step Toward Diversifying

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Continue reading “GW Pharma Takes A Step Toward Diversifying”